Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation

Fig. 4

Five-year patient survival of ‘immune hot’ and high CD45RO/ICOS co-expressed cases in the discovery cohort. a Patients designated ‘immune hot’, expressing high level of CD45RO, ICOS, CD3, CD4, CD8, PD-1 and PD-L1 are in blue, contrasted with red where patented do not express these markers. b Patients expressing high CD45RO/ICOS, blue vs. low CD45RO/ICOS, red. Table below each graph displays number of patients in each group at specified time points, in brackets is the number of censored patients

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us